MONTREAL, May 24, 2011 /CNW/ - Aptilon Corporation ("Aptilon" or the
"Company") (TSX-V: APZ), a leader in online access to, engagement and
interaction with physicians and healthcare professionals on behalf of
pharmaceutical and life sciences companies, today announced that its
indirect wholly-owned subsidiaries, DMD Marketing LP and DMD Marketing
Corp., have come to an agreement to extend the repayment period of the
secured promissory note in the amount of US$27,200,000 issued in
September 2009 in connection with the purchase of substantially all the
assets of Direct Medical Data, LLC. and BLM Incorporated related to
their healthcare marketing services. The original note provided for
monthly installments, and a lump sum payment of approximately
US$12,417,000 on September 15, 2012.
The original note is replaced by a new secured promissory note in the
amount of US$21,750,000, being the balance due under the original note
as of April 14, 2011. The new note bears interest at the rate of 6.9%
per annum and is repayable in increasing monthly installments (ranging
from US$226,000 for the first 9 months to US$600,000 for 11 of the last
12 months) from April 15, 2011 until December 15, 2015. It is secured
and guaranteed in the same manner as the original note.
About Aptilon Corporation
Aptilon enables pharmaceutical, biotech and medical device companies to
effectively reach, message, connect and interact with US physicians and
healthcare professionals on the Internet and over mobile devices via
multiple access channels. Its innovative service offerings provide
targeted impressions and interactions through: video and mobile
detailing, ReachNet℠ Physician Access Channel, the DMD database and
permission-based email services. Top US pharmaceutical companies and
respected healthcare organizations have adopted Aptilon's solutions to
market to, engage and interact with leading healthcare practitioners.
For more information, visit www.aptilon.com.
ReachNetSM is a service mark of Aptilon Corporation.
Neither TSX Venture Exchange nor its Regulation Services Provider (as
that term is defined in the policies of the TSX Venture Exchange)
accepts responsibility for the adequacy or accuracy of this release.
SOURCE Aptilon Corporation
For further information:
Mr. Denis Martineau